Methyl group-donating vitamins elevate 3-o-methyldopa in patients with parkinson disease

Clinical Neuropharmacology

Volumn 36, Issue 2, 2013, Pages 52-54

  Müller, Thomas ^a,b   Jugel, Constanze ^c   Muhlack, Siegfried ^b   Klostermann, Fabian ^c  

^a St Joseph Hospital Berlin Weissensee   (Germany)

^b ST JOSEF HOSPITAL   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

3 O methyldopa; homocysteine; levodopa

Indexed keywords

3 O METHYLDOPA; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; LEVODOPA; PYRIDOXINE;

AGED; ARTICLE; BIOAVAILABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; HUMAN; LOW DRUG DOSE; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN METHYLATION; SYNTHESIS; VITAMIN SUPPLEMENTATION;

AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; BIOLOGICAL MARKERS; COHORT STUDIES; FEMALE; HOMOCYSTEINE; HUMANS; LEVODOPA; MALE; METHYLATION; MIDDLE AGED; PARKINSON DISEASE; PILOT PROJECTS; TYROSINE; VITAMINS;

EID: 84875443981     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0b013e318283fa18     Document Type: Article

References (7)

1. Müller T. Motor complications, levodopa metabolism and progression of Parkinson's disease. Expert Opin Drug Metab Toxicol 2011;7:847-855.
2. Cacciapuoti F. Hyper-homocysteinemia: a novel risk factor or a powerful marker for cardiovascular diseases Pathogenetic and therapeutical uncertainties. J Thromb Thrombolysis 2011;32:82-88.
3. Antonini A, Bondiolotti G, Natuzzi F, et al. Levodopa and 3-OMD levels in Parkinson patients treated with Duodopa. Eur Neuropsychopharmacol 2010;20:683-687.
4. Müller T, Jugel C, Ehret R, et al. Elevation of total homocysteine levels in patients with Parkinson's disease treated with duodenal levodopa/carbidopa gel. J Neural Transm 2011;118:1329-1333.
5. Ho PI, Ashline D, Dhitavat S, et al. Folate deprivation induces neurodegeneration: roles of oxidative stress and increased homocysteine. Neurobiol Dis 2003;14:32-42.
6. Klostermann F, Jugel C, Müller T, et al. Malnutritional neuropathy under intestinal levodopa infusion. J Neural Transm 2012;119:369-372.
7. Zesiewicz TA, Wecker L, Sullivan KL, et al. The controversy concerning plasma homocysteine in Parkinson disease patients treated with levodopa alone or with entacapone: effects of vitamin status. Clin Neuropharmacol 2006;29:106-111.